Outcome in patients with acute myeloid leukemia (AML) ranges from death within a few days
of beginning treatment (treatment related mortality, TRM) to likely cure. The major reason …

Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Management of AML involves choosing between purely palliative care, standard therapy
and investigational therapy (“clinical trial”). Even most older patients likely benefit from …

Evidence suggest that even patients aged 70 or above benefit from specific AML therapy.
The fundamental decision in AML then becomes whether to recommend standard or …

Overview: Evidence suggest that even patients aged 70 or above benefit from specific AML
therapy. The fundamental decision in AML then becomes whether to recommend standard …

Abstract The European LeukemiaNet recently revised both the clinical (2022) and
measurable residual disease testing (2021) guidelines for acute myeloid leukemia (AML) …

Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with an
incidence that increases with age, and a generally poor prognosis. The disease is clinically …

For several decades, few substantial therapeutic advances have been made for patients
with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen …

Opinion statement Approximately 40–45% of younger and 10–20% of older adults with
acute myeloid leukemia (AML) will be cured with current standard chemotherapy. The …

The choice of treatment approach and outcome in acute myeloid leukemia (AML) depends
on the age of the patient. In younger patients, arbitrarily defined as being younger than 60 …